Podium to Practice: ESMO® 2026 – LUNG: OptiTROP-Lung06 study
OR
Studies / Trials Discussed
LBA66 – Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study
Chair
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Amgen.
Studies/trials discussed:
LBA66 – Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.